TY - JOUR
T1 - CYP19 TCT Tri-Nucleotide Del/Del Genotype Is a Susceptibility Marker for Prostate Cancer in a Taiwanese Population
AU - Huang, Yu Chuen
AU - Chen, Marcelo
AU - Lin, Ming Wei
AU - Chung, Ming Yi
AU - Chang, Yen Hwa
AU - Huang, William Ji Shian
AU - Wu, Tony T.
AU - Hsu, Jong Ming
AU - Yang, Stone
AU - Chen, Yi Ming Arthur
N1 - Funding Information:
This research was supported by the Veterans General Hospital, Tsou Foundation, and National Yang-Ming University (VTY) Joint Research Program (grant VTY92-P5-32) managed by the Tsou Foundation and Mackay Memorial Hospital and National Yang-Ming University (MMHYM) Joint Research Program (grant MMHYM93-N010-016) from the Mackay Memorial Hospital.
PY - 2007/5
Y1 - 2007/5
N2 - Objectives: The CYP19 gene encodes aromatase-a key enzyme involved in the conversion of androstenedione/testosterone to estrone/estradiol. In this study, we analyzed the association between the TCT insertion (Ins)/deletion (Del) and TTTA repeat polymorphisms of CYP19 and prostate cancer (PCa). Methods: Automated sequencer with GeneScan software was used to determine the CYP19 gene polymorphisms in peripheral blood mononuclear cell DNA from 244 patients with PCa and 261 age-matched healthy male controls. The distribution of Stage I to IV was 3.4%, 23.8%, 19.6%, and 53.2%, respectively. The Gleason score was 2 to 5 in 22.9%, 6 to 7 in 53.2%, and 8 to 10 in 23.8%. Results: The frequency of the TCT Del/Del genotype in the Taiwanese patients with PCa (12.3%) was significantly greater than that in the controls (5.4%; P = 0.015, odds ratio [OR] 2.43, 95% confidence interval [CI] 1.23 to 4.80). Individuals with a homozygous A1 (seven TTTA repeats) genotype had a significantly greater risk of developing PCa (OR 1.59, 95% CI 1.04 to 2.44, P = 0.044). The frequency of the Ins-A6 (12 TTTA repeats) haplotype was significantly greater in the control group than in the patient group (9.8% versus 6.1%, OR 0.61, 95% CI 0.38 to 0.97). The OR of developing PCa for men with the homozygous Del-A1 diplotype was 2.31 (95% CI 1.10 to 4.83). Conclusions: The results of our study have shown that the CYP19 TCT Del/Del genotype might be a susceptibility marker for PCa. Men with the Ins-A6 haplotype had a lower risk of developing PCa.
AB - Objectives: The CYP19 gene encodes aromatase-a key enzyme involved in the conversion of androstenedione/testosterone to estrone/estradiol. In this study, we analyzed the association between the TCT insertion (Ins)/deletion (Del) and TTTA repeat polymorphisms of CYP19 and prostate cancer (PCa). Methods: Automated sequencer with GeneScan software was used to determine the CYP19 gene polymorphisms in peripheral blood mononuclear cell DNA from 244 patients with PCa and 261 age-matched healthy male controls. The distribution of Stage I to IV was 3.4%, 23.8%, 19.6%, and 53.2%, respectively. The Gleason score was 2 to 5 in 22.9%, 6 to 7 in 53.2%, and 8 to 10 in 23.8%. Results: The frequency of the TCT Del/Del genotype in the Taiwanese patients with PCa (12.3%) was significantly greater than that in the controls (5.4%; P = 0.015, odds ratio [OR] 2.43, 95% confidence interval [CI] 1.23 to 4.80). Individuals with a homozygous A1 (seven TTTA repeats) genotype had a significantly greater risk of developing PCa (OR 1.59, 95% CI 1.04 to 2.44, P = 0.044). The frequency of the Ins-A6 (12 TTTA repeats) haplotype was significantly greater in the control group than in the patient group (9.8% versus 6.1%, OR 0.61, 95% CI 0.38 to 0.97). The OR of developing PCa for men with the homozygous Del-A1 diplotype was 2.31 (95% CI 1.10 to 4.83). Conclusions: The results of our study have shown that the CYP19 TCT Del/Del genotype might be a susceptibility marker for PCa. Men with the Ins-A6 haplotype had a lower risk of developing PCa.
UR - http://www.scopus.com/inward/record.url?scp=34247621265&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2007.02.014
DO - 10.1016/j.urology.2007.02.014
M3 - Article
C2 - 17482958
AN - SCOPUS:34247621265
SN - 0090-4295
VL - 69
SP - 996
EP - 1000
JO - Urology
JF - Urology
IS - 5
ER -
